Figure 2. Chromium-release measurement of ADCC of patient blood samples at different treatment time points. Time- and treatment-dependent enhancement of specific tumor cell lysis mediated by patient-derived NK cells toward naive or cetuximab-coated SCC25 cells (ADCC) (effector [NK]: target [SCC25] cell ratio 20:1 or 40:1). Specific lysis was calculated from radioactive chrome release assay. Data represent mean percent of lysis ± SD of triplicates.